Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention

International Journal of Toxicology

Volumn 29, Issue 2, 2010, Pages 157-164

  Kapetanovic, Izet M ^a   Horn, Thomas L ^b   Johnson, William D ^b   Cwik, Michael J ^b   Detrisac, Carol J ^c   McCormick, David L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

^c Pathology Associates   (United States)

Author keywords

9 cis UAB30; Cancer chemopreventive agent; Oncogenicity; p53(+ ) mouse; Pharmacokinetics; Retinoid

Indexed keywords

4 CRESIDINE; 8 [3',4' DIHYDRO 1'(2'H) NAPHTHALEN 1' YLIDENE] 3,7 DIMETHYL 2,4,6 OCTATRIENOIC ACID]; ANTINEOPLASTIC AGENT; CARCINOGEN; RETINOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CARCINOGENICITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEPATOMEGALY; MALE; MOUSE; NONHUMAN;

ANIMALS; AREA UNDER CURVE; BREAST NEOPLASMS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NAPHTHALENES; RETINOID X RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE; MUS;

EID: 77951104122     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809360070     Document Type: Article

References (26)

1. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271-1279.
2. Yang LM, Tin-U C, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999;4:377-388.
3. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 2006;13:51-68.
4. Zusi FC, Lorenzi MV, Vivat-Hannah V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today. 2002;7:1165-1174. (Pubitemid 35430153)
5. Tanaka T, De Luca LM. Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res. 2009;69:4945-4947.
6. Abou-Issa H, Duruibe VA. Anticarcinogenic effect of retinoids on 7,12-dimethylbenz(a)anthracene-induced mammary tumor induction, and its relationship to cyclic AMP-dependent protein kinase. Biochem Biophys Res Commun. 1986;135:116-123. (Pubitemid 16063977)
7. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 1996;56:5566-5570.
8. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994;54:4614-4617.
9. McCormick DL, Rao KV, Steele VE, Lubet RA, Kelloff GJ, Bosland MC. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 1999;59:521-524. (Pubitemid 29076042)
10. Horn TL, Torres KE, Naylor JM, et al. Subchronic toxicity and toxicogenomics evaluation of tamoxifen citrate + bexarotene in female rats. Toxicol Sci. 2007;99:612-627.
11. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004;4:180-188.
12. Muccio DD, Brouillette WJ, Breitman TR, et al. Conformationally defined retinoic acid analogues, 4: potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem. 1998;41:1679-1687.
13. Atigadda VR, Vines KK, Grubbs CJ, et al. Conformationally defined retinoic acid analogues, 5: large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3′,4′-Dihydro- 1′(2′H)-naphthalen-1′-ylidene)-3,7-dimethyl-2,4, 6-octatrienoic acid (9cUAB30). J Med Chem. 2003;46:3766-3769.
14. Grubbs CJ, Hill DL, Bland KI, et al. 9cUAB30, and RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett. 2003;201:17-24.
15. Esteva FJ, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003;21:999-1006. (Pubitemid 46594127)
16. McDonald J, French JE, Gerson RJ, et al. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci. 2004;77:188-194.
17. Storer RD, French JE, Haseman J, et al. p53+/- hemizygous knockout mouse: overview of available data. Toxicol Pathol. 2001;29:30-50. (Pubitemid 33026793)
18. Jacobson-Kram D, Sistare FD, Jacobs AC. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol. 2004;32:49-52. (Pubitemid 38437567)
19. Johnson WD, Dooley L, Morrissey RL, et al. Oncogenicity evaluations of chemopreventive soy components in p53(+/-) (p53 knockout) mice. Int J Toxicol. 2006;25:219-228. (Pubitemid 44105298)
20. Wang E-J, Mandakas G, Palamanda J, et al. Temporal evaluation of CYP mRNA in mice administered with prototypical P450 inducers: comparison with conventional protein/enzyme methods. Drug Chem Toxicol. 2008;31:501-513.
21. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988;16:303-309.
22. Nedelman JR, Gibiansky E, Lau DTW. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res. 1995;12:124-128.
23. Jiang W, Deng W, Bailey SK, et al. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther. 2009;8:289-298.
24. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76:215-228.
25. Gorman GS, Coward L, Kerstner-Wood C, et al. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007;35:1157-1164.
26. Hewitt NJ, LeCluyse EL, Fergesun SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica. 2007;37:1196-1224.